These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H; Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356 [TBL] [Abstract][Full Text] [Related]
6. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy. Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837 [TBL] [Abstract][Full Text] [Related]
7. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028 [TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha treatment of children and young adults with chronic hepatitis delta virus (HDV) infection. Aziz S; Rajper J; Noor-ul-Ain W; Mehnaz A; Masroor M; Chang MH J Coll Physicians Surg Pak; 2011 Dec; 21(12):735-40. PubMed ID: 22166693 [TBL] [Abstract][Full Text] [Related]
9. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Mederacke I; Yurdaydin C; Dalekos GN; Bremer B; Erhardt A; Cakaloglu Y; Yalcin K; Gurel S; Zeuzem S; Zachou K; Bozkaya H; Dienes HP; Manns MP; Wedemeyer H; Antivir Ther; 2012; 17(2):305-12. PubMed ID: 22293066 [TBL] [Abstract][Full Text] [Related]
10. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir. Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283 [TBL] [Abstract][Full Text] [Related]
11. Current management of delta hepatitis. Rizzetto M Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865 [TBL] [Abstract][Full Text] [Related]
12. Treatment of delta hepatitis. Gunsar F Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855 [TBL] [Abstract][Full Text] [Related]
13. Resistance of hepatitis delta virus replication to interferon-alpha treatment in transfected human cells. Ilan Y; Klein A; Taylor J; Tur-Kaspa R J Infect Dis; 1992 Nov; 166(5):1164-6. PubMed ID: 1328404 [TBL] [Abstract][Full Text] [Related]
14. HDV evolution-will viral resistance be an issue in HDV infection? Tabernero D; Cortese MF; Buti M; Rodriguez-Frias F Curr Opin Virol; 2018 Oct; 32():100-107. PubMed ID: 30415162 [TBL] [Abstract][Full Text] [Related]
15. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. Mansour W; Ducancelle A; Le Gal F; Le Guillou-Guillemette H; Abgueguen P; Pivert A; Calès P; Gordien E; Lunel F J Clin Virol; 2010 Jan; 47(1):97-9. PubMed ID: 19914127 [TBL] [Abstract][Full Text] [Related]
16. Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. Zhang Z; Ni Y; Lempp FA; Walter L; Mutz P; Bartenschlager R; Urban S J Hepatol; 2022 Oct; 77(4):957-966. PubMed ID: 35636579 [TBL] [Abstract][Full Text] [Related]
17. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. Le Gal F; Gordien E; Affolabi D; Hanslik T; Alloui C; Dény P; Gault E J Clin Microbiol; 2005 May; 43(5):2363-9. PubMed ID: 15872267 [TBL] [Abstract][Full Text] [Related]
18. Peginterferon plus adefovir versus either drug alone for hepatitis delta. Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP; N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724 [TBL] [Abstract][Full Text] [Related]
19. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. Zhang Z; Urban S J Hepatol; 2021 Mar; 74(3):686-699. PubMed ID: 33276031 [TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. Samiullah S; Bikharam D; Nasreen World J Gastroenterol; 2012 Oct; 18(40):5793-8. PubMed ID: 23155322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]